Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

SAVETHEHEART Microfluidics-assisted synthesis of Dapagliflozin-loaded liposomes for heart fibrosis: Development of a 3D bioprinted multicellular in vitro model

Coordinator
Academisch Ziekenhuis Groningen, Netherlands
Runs
15 September 2024 to 14 September 2026
Status
Running
EU funding
€188k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101146615

What the project is doing

In the project's own words, from its summary on CORDIS.

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with half of CVDs deaths being caused by coronary artery disease. Myocardial infarction is the most common cause of cardiac insufficiency, leading to fibrosis and ultimately heart failure. Since current therapies for cardiac fibrosis have limitations, there is a need for more effective strategies. Gliflozins (e.g., Dapagliflozin and Empagliflozin), hypoglycemic agents and SGLT2 inhibitors usually used for the treatment of type 2 diabetes, have been shown in recent clinical trials (i.e., DAPA-HF, DELIVER, EMPEROR-Reduced, EMPEROR-Preserved) to reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with reduced and preserved ejection fraction, regardless of diabetes status.

They have also been shown to ameliorate myocardial fibrosis post-ischemia. Nevertheless, most of the underlying mechanisms of these benefits remain elusive and the potential adverse effects of the systemic administration of gliflozins must be recognised. In this regard, the use of liposomes as in situ injectable drug delivery systems offers many potential advantages for the therapy of myocardial infarction. Therefore, the SAVETHEHEART project aims to develop a new therapeutic approach for the efficient treatment of cardiac fibrosis by using liposomes, produced by microfluidics to encapsulate Dapagliflozin (DAPA).

Their effect will be studied in a 3D model of cardiac fibrosis, that will be obtained by bioprinting a biomimetic type I collagen hydrogel, bioengineered with human induced pluripotent stem cells-derived cardiomyocytes, myofibroblasts and endothelial cells, and cultured under perfusion and hypoxic conditions to better mimic a fibrotic response. Understanding cell behaviour in the proposed setting, this work opens perspective to the optimization of injectable DAPA-liposome formulations, intended as an innovative therapeutic strategy for the treatment of cardiac fibrosis.

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis GroningenGroningenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI